Australian biotechnology company Vaxine Pty Ltd on Tuesday announced plans to collaborate for the supply of its COVID-19 Vaccine, Covax-19 (Spikogen) and the co-development of COVID-19/influenza combo vaccine under a memorandum of understanding (MOU) with Prestige Biopharma Limited, a Singapore-based biopharmaceutical company.

Vaxine's state-of-the-art recombinant protein vaccine against COVID-19 uses insect cells and includes its proprietary Advax polysaccharide adjuvant. Spikogen showed efficacy against infection by the Delta variant in Phase 3 clinical trials and is in use in the Middle East.

In December 2021, the Australian Therapeutic Goods Administration (TGA) awarded provisional determination allowing an application to be lodged for provisional approval for Spikogen. Regulatory submissions are similarly underway in many other countries in parallel.

Through the MOU, Prestige will combine its global scale vaccine manufacturing capacity & research expertise with Vaxine's vaccine technologies against COVID-19, seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, dengue, malaria, allergy and cancer.

The partners will initially focus on manufacturing and commercialization of Vaxine's Covid-19 vaccine and then as Covid-19 enters an endemic phase development of a next generation Covid-19/influenza combo vaccine as well as other vaccine projects.